User profiles for VANESSA INNAO

Vanessa Innao

University of Messina
Verified email at unime.it
Cited by 1726

Anticancer activity of curcumin and its analogues: preclinical and clinical studies

A Allegra, V Innao, S Russo, D Gerace… - Cancer …, 2017 - Taylor & Francis
Curcumin has been shown to have a wide variety of therapeutic effects, ranging from anti-inflammatory,
chemopreventive, anti-proliferative, and anti-metastatic. This review provides an …

[HTML][HTML] Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma

C Musolino, A Allegra, V Innao, AG Allegra… - Mediators of …, 2017 - hindawi.com
Multiple myeloma (MM) is typically exemplified by a desynchronized cytokine system with
increased levels of inflammatory cytokines. We focused on the contrast between inflammatory …

[HTML][HTML] Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies

A Allegra, V Innao, AG Allegra, C Musolino - Annals of hematology, 2020 - Springer
In October 2019, a viral infectious disease appeared in the city of Wuhan in China. A new
betacoronavirus, SARS-CoV-2, has been recognized as the responsible pathogen in this …

Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma

…, M Zappalą, S Grasso, C Musolino, V Innao… - Pharmacology & …, 2018 - Elsevier
The ubiquitin-proteasome system (UPS) is the major non-lysosomal proteolytic system for
the degradation of abnormal or damaged proteins no longer required. The proteasome is …

The cancer stem cell hypothesis: a guide to potential molecular targets

A Allegra, A Alonci, G Penna, V Innao… - Cancer …, 2014 - Taylor & Francis
Common cancer theories hold that tumor is an uncontrolled somatic cell proliferation caused
by the progressive addition of random mutations in critical genes that control cell growth. …

New orally active proteasome inhibitors in multiple myeloma

A Allegra, A Alonci, D Gerace, S Russo, V Innao… - Leukemia research, 2014 - Elsevier
Bortezomib is the first proteasome inhibitor approved for the therapy of multiple myeloma (MM).
Although Bortezomib has renovated the treatment of MM, a considerable proportion of …

Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw

…, M Mania, A D'Ascola, A Avenoso, V Innao… - Annals of …, 2018 - Springer
Bisphosphonates are formidable inhibitors of osteoclast-mediated bone resorption employed
for therapy of multiple myeloma (MM) subjects with osteolytic lesions. Osteonecrosis of the …

Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

…, A Alonci, S Russo, B Greve, V Innao… - European journal of …, 2013 - Wiley Online Library
Despite recent treatments, such as bortezomib, thalidomide, and lenalidomide, therapy of
multiple myeloma ( MM ) is limited, and MM remains an incurable disease associated with high …

Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells

A Allegra, V Innao, D Gerace, D Vaddinelli… - Blood Cells, Molecules …, 2016 - Elsevier
Hematological malignancies frequently express cancer-associated antigens that are shared
with normal cells. Such tumor cells elude the host immune system because several T cells …

[HTML][HTML] Formaldehyde exposure and acute myeloid leukemia: a review of the literature

A Allegra, G Spatari, S Mattioli, S Curti, V Innao, R Ettari… - Medicina, 2019 - mdpi.com
Background and objective: The aim of the present study was to evaluate associations between
cumulative and peak formaldehyde exposure and occurrence of acute myeloid leukemia. …